Asbury Automotive Group Inc.

▲ Bull Case

• ◆GPU normalization complete; annuity P&S and F&I streams provide earnings floor. Six consecutive quarters of 16.7–17.9% gross margin stability confirms the post-COVID normalization has reset at a durable floor. P&S (growing with a ~12.5-year average vehicle age) and F&I (TCA recurring contracts) now represent ~65–75% of gross profit despite being ~25% of revenue — the annuity streams insulate earnings from further vehicle-price compression.
• ◆Herb Chambers at 0.6x revenue is the best acquisition in ABG's history; TCA rollout adds $30–50M incremental EBITDA. Paying $1.76B for $2.9B in luxury revenue in Greater Boston is demonstrably better value than Park Place. TCA deployment to 33 Herb Chambers dealerships targets 2026 completion; incremental F&I penetration on high-income Boston luxury customers is the highest-PVR opportunity in ABG's portfolio.
• ◆Buyback accretion at 6.7x P/E: 15% unleveraged return per dollar of repurchase capital. Float reduction from 22.4M (FY2022) to ~15.1M (FY2030E) represents a 33% reduction in outstanding shares. At flat earnings, this alone compounds EPS by 10%+ annually. Combined with the Herb Chambers ramp and TCA optionality, the combined 2-year EPS trajectory ($26.74 → $37.26) represents a 39% EPS increase with zero assumption of multiple expansion.

▼ Bear Case

• ◆Tariff-driven H2 2026 SAAR air pocket turns Q1 2026's +42% EPS into a misleading signal. The tariff pull-forward artificially inflated Q1 2026 volumes. If SAAR falls to 14.0–14.5M in H2 2026 as higher MSRPs deter buyers, GPU could fall below $2,500/unit — a $90M+ gross profit headwind — while volume simultaneously declines. Consensus FY2026 EPS at $26.52 would be at risk, and the 'GPU floor' narrative would be shattered.
• ◆Elevated inventory ($2.1B) + industry over-production = GPU pressure not yet over. ABG's inventory rose from $875M (FY2020) to $2,136M (FY2025). Elevated industry inventory enables consumers to negotiate, compressing GPU toward pre-pandemic levels of $1,500–2,500/unit. Each $500/unit decline on 181,000 units = $90M gross profit. The bear case ($2,300–2,600/unit GPU) would reduce EBITDA from $943M to $850–870M, compressing equity value to $90–155/share at 6x EV/EBITDA.
• ◆Leverage ($5.85B total; $484M near-term maturity) + CEO succession uncertainty creates binary risk at a cyclical inflection. ABG's total debt is 6.2x EBITDA on a reported basis (3.3x on adjusted basis). The first 12 months of Dan Clara's CEO tenure coincide with potential SAAR softening, Herb Chambers integration execution, and a $484M debt maturity. If all three go wrong simultaneously, leverage ratios approach covenant thresholds and buybacks must be suspended.

“The central question: Is ABG's 6.7x P/E a value trap or a genuine discount? The bear view (consensus Hold, $241 avg. target = only 27% upside): Analysts focus on near-term earnings risk and believe fair value is somewhat higher than current price but the risk/reward is not asymmetrically attractive. The core concern is that auto retail cycles have faded faster than expected post-COVID, and macro headwinds (tariffs, rates, affordability) suggest proximity to the next trough. The bull view (variant investors): ABG's discount to peers (6.7x vs. 9.3–14.1x for AN/LAD/GPI/PAG) is too wide given (1) Herb Chambers acquisition quality, (2) TCA's insurance-adjacent business model, and (3) buyback math at current prices. Variant investors argue TCA is being priced as dealer GP, not as recurring insurance float, and that the market is not distinguishing between ABG's structural annuity streams and the cyclical GPU component. The open debate: No analyst has published a formal sum-of-the-parts valuation separately attributing a higher multiple to TCA. Re-rating requires management action (investor day, segment disclosure) rather than just earnings execution.”

• ◆TCA active contracts reach 2.0M+ — Validates insurance re-rating narrative; could trigger analyst coverage upgrade (12–18 months)
• ◆Herb Chambers H1 2026 EPS contribution exceeds analyst models — Removes integration uncertainty; re-rates acquisition quality (6–9 months)
• ◆$300M+ buyback in FY2026 confirmed in earnings — EPS accretion math visible; demonstrates capital discipline at current price (3–6 months)
• ◆FY2026 full-year EPS guidance above $26.52 consensus — Removes tariff/GPU downside fears; base case confirmed (9–12 months)

• ◆SAAR contraction H2 2026 from tariff air pocket (HIGH prob/impact) — $90–150M EBITDA headwind; mitigated by P&S floor and TCA recurring contracts
• ◆GPU falls below $2,500/unit amid elevated inventory (MEDIUM-HIGH prob/HIGH impact) — $90M per $500/unit decline; mitigated by F&I/P&S floor
• ◆CEO Dan Clara execution stumble on Herb Chambers integration (MEDIUM prob/impact) — Mitigated by David Hult as Executive Chairman
• ◆Debt refinancing at adverse rates with $484M near-term maturity (MEDIUM prob/impact) — Mitigated by $570M annual FCF and revolving credit